Value Development and Key Trends of Acne Medication Market 2017-2025

A fresh report titled “ Acne Medication Market  ” has been presented by KD market research. It evaluates the key market trends, advantages, and factors that are pushing the overall growth of the market. The report also analyzes the different segments along with major geographies that have more demand for Acne Medication Market. The competition analysis is also a major part of the report. 

Acne or acne vulgaris is a skin disease caused due to clogging of hair follicles with dead skin cells and oil from skin cells. This disease is characterized with pimples, blackheads, oily skin, and scarring. There are two types of acne-non-inflammatory and inflammatory acne, where the latter takes longer duration to heal and can cause permanent effects on the skin. Acne medications are either applied directly, which are present in formulations, or taken in the form of oral pills. These medications work by reducing inflammation and oil production. They also fight with bacteria finally preventing scarring. The common acne medications include retinoids, antibiotics, isotretinoin, benzoyl peroxide, and others.

Request sample copy@ https://www.kdmarketresearch.com/sample/3227

The global acne medication market was valued at $8,017 million in 2017, and is projected to reach $10,929 million by 2025 at a CAGR of 3.9% from 2018 to 2025. Increase in prevalence of acne diseases is the major factor that contributes toward the growth of the acne medication market. Moreover, other factors that fuel the market growth include unhealthy urban lifestyle, and presence of robust acne medications in pipeline. However, side-effects associated with the use of acne medications and presence of alternative treatment impede the market growth.Conversely, development of effective medications with lesser side effects and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market growth.

The global acne medication market is segmented into therapeutic class, formulation, type, acne type, distribution channel, and region. Based on therapeutic class, the market is divided into retinoids, antibiotics, salicylic acid, benzoyl peroxide, and others. The retinoids segment is further classified into topical retinoid & combination retinoid and oral retinoid (isotretinoin). The antibiotics segment is further sub-segmented into topical antibiotics & combination antibiotics and oral antibiotics. Based on the formulation, the market is bifurcated into topical medication and oral medication. Based on type, the market is categorized into prescription medicine and over-the-counter (OTC) medicine. By acne type, the market is divided into non-inflammatory and inflammatory acne. The distribution channel covered in the study include grocery store, pharmacy & drug store, and e-commerce. Based on region, it is analyzed for across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

-The study provides an in-depth analysis of the global acne medication market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.

-Comprehensive analysis of factors that drive and restrict the market growth is provided.

-Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.

-Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key market segments

By Therapeutic Class

-Retinoids
-Topical Retinoid & Combination Retinoid
-Oral Retinoid (Isotretinoin)
-Antibiotics
-Topical Antibiotic & Combination Antibiotics
-Oral Antibiotics
-Salicylic Acid
-Benzoyl Peroxide
-Others

By Formulation

-Topical Medication
-Oral Medication

By Type

-Prescription Medicine
-Over-the-counter (OTC) Medicine

By Acne Type

-Inflammatory Acne
-Non-inflammatory Acne

By Distribution Channel

-Grocery Store
-Pharmacy & Drug Store
-e-Commerce

By Region

-North America
-U.S.
-Canada
-Mexico
-Europe
-Germany
-France
-UK
-Italy
-Spain
-Rest of Europe
-Asia-Pacific
-Japan
-China
-India
-Australia
-South Korea
-Rest of Asia-Pacific
-LAMEA
-Brazil
-Saudi Arabia
-South Africa
-Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

-Allergan Plc.
-Nestle S.A.
-Johnson & Johnson
-Mayne Pharma Group Limited
-Mylan N.V.
-Pfizer Inc.
-GlaxoSmithKline Plc
-Sun Pharmaceutical Industries Limited
-Teva Pharmaceutical Industries Ltd.
-Valeant Pharmaceuticals International, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

-Daiichi Sankyo Company, Ltd.
-Ranbaxy Laboratories Limited
-Medicis Pharmaceutical Corporation
-Foamix Pharmaceuticals
-Prestium Pharma, Inc.
-BioPharmX, Inc.

Browse Complete Research Report with toc@ https://www.kdmarketresearch.com/report/3227/acne-medication-market-amr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. By Therapeutic Class
1.3.2. By Formulation
1.3.3. By Type
1.3.4. By Acne Type
1.3.5. By Distribution Channel
1.3.6. By Region
1.3.7. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Top player positioning, 2017
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of acne diseases
3.4.1.2. Unhealthy urban lifestyle
3.4.1.3. Rise in focus on skin care products

3.4.2. Restraints

3.4.2.1. Side effects associated with acne medications
3.4.2.2. Presence of alternatives for acne treatment

3.4.3. Opportunities

3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of therapeutics with lesser side effects

3.4.4. Impact analyses

3.5. Clinical trials
3.6. Patent analysis (2013-2018)

3.6.1. Patent analysis, by year
3.6.2. Patent analysis for China, by year

CHAPTER 4: ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Retinoid

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Topical & combination retinoid

4.2.2.1.1. Market size and forecast, by region

4.2.2.2. Oral retinoid (Isotretinoin)

4.2.2.2.1. Market size and forecast, by region

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Antibiotics

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Topical & combination antibiotics

4.3.2.1.1. Market size and forecast, by region

4.3.2.2. Oral antibiotics

4.3.2.2.1. Market size and forecast, by region

4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

4.4. Salicylic acid

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Benzoyl Peroxide

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Other medications

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: ACNE MEDICATION MARKET, BY FORMULATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Topical medications

5.2.1. Market size and forecast, by region

5.3. Oral medications

5.3.1. Market size and forecast, by region

CHAPTER 6: ACNE MEDICATION MARKET, BY TYPE

6.1. Overview

6.1.1. Market size and forecast

6.2. Prescription medicines

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Over-the-counter medicines

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: ACNE MEDICATION MARKET, BY ACNE TYPE

7.1. Overview

7.1.1. Market size and forecast

7.2. Non-inflammatory acne

7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country

7.3. Inflammatory acne

7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country

CHAPTER 8: SOURCES: PRIMARY & SECONDARY RESEARCH AND AMR ANALYSIS ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview

8.1.1. Market size and forecast

8.2. Grocery store

8.2.1. Market size and forecast, by region
8.2.2. Market analysis, by country

8.3. Pharmacy & drug store

8.3.1. Market size and forecast, by region
8.3.2. Market analysis, by country

8.4. e-Commerce

8.4.1. Market size and forecast, by region
8.4.2. Market analysis, by country

CHAPTER 9: ACNE MEDICATION MARKET, BY REGION

9.1. Overview

9.1.1. Market size and forecast

9.2. North America

9.2.1. Key market trends, growth factors and opportunities
9.2.2. North America acne medication market, by country

9.2.2.1. U.S.

9.2.2.1.1. Market size and forecast, by therapeutic class
9.2.2.1.2. Market size and forecast, by type
9.2.2.1.3. Market size and forecast, by acne type
9.2.2.1.4. Market size and forecast, by distribution channel

9.2.2.2. Canada

9.2.2.2.1. Market size and forecast, by therapeutic class
9.2.2.2.2. Market size and forecast, by type
9.2.2.2.3. Market size and forecast, by acne type
9.2.2.2.4. Market size and forecast, by distribution channel

9.2.2.3. Mexico

9.2.2.3.1. Market size and forecast, by therapeutic class
9.2.2.3.2. Market size and forecast, by type
9.2.2.3.3. Market size and forecast, by acne type
9.2.2.3.4. Market size and forecast, by distribution channel

9.2.3. North America market size and forecast, by therapeutic class
9.2.4. North America market size and forecast, by formulation
9.2.5. North America market size and forecast, by type
9.2.6. North America market size and forecast, by acne type
9.2.7. North America market size and forecast, by distribution channel

9.3. Europe

9.3.1. Key market trends, growth factors and opportunities
9.3.2. Europe market size and forecast, by country

9.3.2.1. Germany

9.3.2.1.1. Market size and forecast, by therapeutic class
9.3.2.1.2. Market size and forecast, by type
9.3.2.1.3. Market size and forecast, by acne type
9.3.2.1.4. Market size and forecast, by distribution channel

9.3.2.2. France

9.3.2.2.1. Market size and forecast, by therapeutic class
9.3.2.2.2. Market size and forecast, by type
9.3.2.2.3. Market size and forecast, by acne type
9.3.2.2.4. Market size and forecast, by distribution channel

9.3.2.3. UK

9.3.2.3.1. Market size and forecast, by therapeutic class
9.3.2.3.2. Market size and forecast, by type
9.3.2.3.3. Market size and forecast, by acne type
9.3.2.3.4. Market size and forecast, by distribution channel

9.3.2.4. Italy

9.3.2.4.1. Market size and forecast, by therapeutic class
9.3.2.4.2. Market size and forecast, by type
9.3.2.4.3. Market size and forecast, by acne type
9.3.2.4.4. Market size and forecast, by distribution channel

9.3.2.5. Spain

9.3.2.5.1. Market size and forecast, by therapeutic class
9.3.2.5.2. Market size and forecast, by type
9.3.2.5.3. Market size and forecast, by acne type
9.3.2.5.4. Market size and forecast, by distribution channel

9.3.3. Rest of Europe

9.3.3.1.1. Market size and forecast, by therapeutic class
9.3.3.1.2. Market size and forecast, by type
9.3.3.1.3. Market size and forecast, by acne type
9.3.3.1.4. Market size and forecast, by distribution channel

9.3.4. Europe market size and forecast, by therapeutic class
9.3.5. Europe market size and forecast, by formulation
9.3.6. Europe market size and forecast, by type
9.3.7. Europe market size and forecast, by acne type
9.3.8. Europe market size and forecast, by distribution channel

9.4. Asia-Pacific

9.4.1. Key market trends, growth factors and opportunities
9.4.2. Asia-Pacific market size and forecast, by country

9.4.2.1. Japan

9.4.2.1.1. Market size and forecast, by therapeutic class
9.4.2.1.2. Market size and forecast, by type
9.4.2.1.3. Market size and forecast, by acne type
9.4.2.1.4. Market size and forecast, by distribution channel

9.4.2.2. China

9.4.2.2.1. Market size and forecast, by therapeutic class
9.4.2.2.2. Market size and forecast, by type
9.4.2.2.3. Market size and forecast, by acne type
9.4.2.2.4. Market size and forecast, by distribution channel

9.4.2.3. India

9.4.2.3.1. Market size and forecast, by therapeutic class
9.4.2.3.2. Market size and forecast, by type
9.4.2.3.3. Market size and forecast, by acne type
9.4.2.3.4. Market size and forecast, by distribution channel

9.4.2.4. Australia

9.4.2.4.1. Market size and forecast, by therapeutic class
9.4.2.4.2. Market size and forecast, by type
9.4.2.4.3. Market size and forecast, by acne type
9.4.2.4.4. Market size and forecast, by distribution channel

9.4.2.5. South Korea

9.4.2.5.1. Market size and forecast, by therapeutic class
9.4.2.5.2. Market size and forecast, by type
9.4.2.5.3. Market size and forecast, by acne type
9.4.2.5.4. Market size and forecast, by distribution channel

9.4.2.6. Rest of Asia-Pacific

9.4.2.6.1. Market size and forecast, by therapeutic class
9.4.2.6.2. Market size and forecast, by type
9.4.2.6.3. Market size and forecast, by acne type
9.4.2.6.4. Market size and forecast, by distribution channel

9.4.3. Asia-Pacific market size and forecast, by therapeutic class
9.4.4. Asia-Pacific market size and forecast, by formulation
9.4.5. Asia-Pacific market size and forecast, by type
9.4.6. Asia-Pacific market size and forecast, by acne type
9.4.7. Asia-Pacific market size and forecast, by distribution channel

9.5. LAMEA

9.5.1. Key market trends, growth factors and opportunities
9.5.2. LAMEA market size and forecast, by country

9.5.2.1. Brazil

9.5.2.1.1. Market size and forecast, by therapeutic class
9.5.2.1.2. Market size and forecast, by type
9.5.2.1.3. Market size and forecast, by acne type
9.5.2.1.4. Market size and forecast, by distribution channel

9.5.2.2. Saudi Arabia

9.5.2.2.1. Market size and forecast, by therapeutic class
9.5.2.2.2. Market size and forecast, by type
9.5.2.2.3. Market size and forecast, by acne type
9.5.2.2.4. Market size and forecast, by distribution channel

9.5.2.3. South Africa

9.5.2.3.1. Market size and forecast, by therapeutic class
9.5.2.3.2. Market size and forecast, by type
9.5.2.3.3. Market size and forecast, by acne type
9.5.2.3.4. Market size and forecast, by distribution channel

9.5.2.4. Rest of LAMEA

9.5.2.4.1. Market size and forecast, by therapeutic class
9.5.2.4.2. Market size and forecast, by type
9.5.2.4.3. Market size and forecast, by acne type
9.5.2.4.4. Market size and forecast, by distribution channel

9.5.3. LAMEA market size and forecast, by therapeutic class
9.5.4. LAMEA market size and forecast, by formulation
9.5.5. LAMEA market size and forecast, by type
9.5.6. LAMEA market size and forecast, by acne type
9.5.7. LAMEA market size and forecast, by distribution channel

CHAPTER 10: COMPANY PROFILES

10.1. Allergan Plc

10.1.1. Company overview
10.1.2. Company snapshot
10.1.3. Operating business segments
10.1.4. Product portfolio
10.1.5. Business performance
10.1.6. Key strategic moves and developments

10.2. Nestle S.A. (Galderma S.A.)

10.2.1. Company overview
10.2.2. Company snapshot
10.2.3. Operating business segments
10.2.4. Product portfolio
10.2.5. Business performance
10.2.6. Key strategic moves and developments

10.3. Johnson & Johnson

10.3.1. Company overview
10.3.2. Company snapshot
10.3.3. Operating business segments
10.3.4. Product portfolio
10.3.5. Business performance

10.4. Mayne Pharma Group Limited

10.4.1. Company overview
10.4.2. Company snapshot
10.4.3. Operating business segments
10.4.4. Product portfolio
10.4.5. Business performance
10.4.6. Key strategic moves and developments

10.5. Mylan N.V.

10.5.1. Company overview
10.5.2. Company snapshot
10.5.3. Operating business segments
10.5.4. Product portfolio
10.5.5. Business performance

10.6. Pfizer Inc.

10.6.1. Company overview
10.6.2. Company snapshot
10.6.3. Operating business segments
10.6.4. Product portfolio
10.6.5. Business performance
10.6.6.

10.7. GlaxoSmithKline Plc (Stiefel Laboratories, Inc.)

10.7.1. Company overview
10.7.2. Company snapshot
10.7.3. Operating business segments
10.7.4. Product portfolio
10.7.5. Business performance

10.8. Sun Pharmaceutical Industries Limited

10.8.1. Company overview
10.8.2. Company snapshot
10.8.3. Operating business segments
10.8.4. Product portfolio
10.8.5. Business performance
10.8.6. Key strategic moves and developments

10.9. Teva Pharmaceutical Industries Ltd.

10.9.1. Company overview
10.9.2. Company snapshot
10.9.3. Operating business segments
10.9.4. Product portfolio
10.9.5. Business performance
10.9.6. Key strategic moves and developments

10.10. Valeant Pharmaceuticals International, Inc.

10.10.1. Company overview
10.10.2. Company snapshot
10.10.3. Operating business segments
10.10.4. Product portfolio
10.10.5. Business performance
10.10.6. Key strategic moves and developments

Request for Exclusive Discount @ https://www.kdmarketresearch.com/discount/3227

About Us:

KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

Contact us -

KD Market Research

150 State Street, Albany,

New York, USA 12207

Website: www.kdmarketresearch.com

Email id-  sales@kdmarketresearch.com

More - https://kdmarketresearch.blogspot.com/